SARS-CoV-2 (COVID-19) Nucleocapsid Antibody

• Catalog Number: orb1239972
• Category: Antibodies
• Description: SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
• Species/Host: Rabbit
• Clonality: Polyclonal
• Tested applications: ELISA, WB
• Reactivity: Virus
• Isotype: IgG
• Immunogen: Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (orb1239972) was raised against a peptide corresponding to 17 amino acids near the center of SARS-CoV-2 (COVID-19) Nucleocapsid protein. The immunogen is located within 230-280 amino acids of SARS-CoV-2 (COVID-19) Nucleocapsid protein.
• Concentration: 1 mg/mL
• Form/Appearance: Liquid
• Conjugation: Unconjugated
• Target: N
• NCBI: QHD43423
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Buffer/Preservatives: SARS-CoV-2 (COVID-19) Nucleocapsid Antibody is supplied in PBS containing 0.02% sodium azide.
• Alternative names: SARS-CoV-2 (COVID-19) Nucleocapsid antibody: Sever
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient (Sun et al., 2020). Detection of SARS-CoV-2 nucleocapsid protein by anti-SARS-COV-2 nucleocapsid antibodies (orb1239972, 0.02 µg/mL, A

B) or SARS-CoV-2 Spike S1 antibodies (orb1239995, 1 µg/mL D

E) in adjacent sections of autopsy lung tissue from COVID-19 deceased patient. Negative control staining on autopsy lung tissue from patient who died from non-COVID-19 pneumonia is shown for Nucleocapsid protein (C) or Spike protein (F). Negative control using normal rabbit immunoglobulin on COVID-19 autopsy tissue is presented (G). DAB chromogen and hematoxylin counterstain are used. Scale bars: 50μM in A, C, D, F, G; 20 µM in B and E.

Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient. Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (orb1239972, 0.02 µg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 40X magnification).

Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in Human Lung Tissue from the COVID-19 Patient. Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody (orb1239972, 0.02 µg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Dr. Hallgeir Rui, MCW) (Picture shown in 63X magnification).

Western Blot Validation with SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein. Loading: 50 ng per lane of SARS-CoV-2 (COVID-19) Nucleocapsid recombinant protein. Antibodies: SARS-CoV-2 (COVID-19) Nucleocapsid, orb1239972, 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.5 µg/mL, Lane 2: 1 µg/mL and Lane 3: 2 µg/mL.